

COVID-19 (mRNA)

COVID-19 mRNA Vaccine mRNA-1273

Supplier: Moderna

INDICATIONS:

- Vaccination will occur in phases. Sequencing of populations for whom the vaccine is currently indicated in British Columbia is available on the BCCDC [COVID-19 Vaccine Eligibility](#) page.

The vaccine is not approved for use in those less than 18 years of age.

DOSES AND SCHEDULE:

Adults 18 years of age and older: 2 doses given as 0.5 mL IM, 35 days apart.^{A, B, C}

ADMINISTRATION:

No reconstitution required.

Storage and Handling:

- The vaccine can be stored at:
 - -20°C (-25°C to -15°C) up to the end of its expiry date, kept in the original packaging and protected from light. Do not store on dry ice.
 - +2°C to +8°C for up to 30 days prior to first use, protected from light.
 - Room temperature (up to +25°C) for up to 12 hours.
 - After first vial puncture, the vaccine must be used **within 6 hours**.
 - The vaccine can be pre-loaded into a syringe for up to 6 hours.
 - Ensure that the vial/syringe is clearly labelled with the date and time of first vial entry.
- Product should be thawed/held prior to use, in one of the following three ways:
 - From the freezer to room temperature; will require 1 hour to thaw
 - From the freezer to the refrigerator; will require 2 hours and 30 minutes to thaw, and then requires at least 15 minutes at room temperature prior to administration.
 - Swirl the vial gently after thawing and between each withdrawal. Do not shake.
- Do not refreeze thawed vials.
- Note: If there is enough vaccine left in the vial for a complete 0.5 mL dose after 10 doses have been removed from the vial, another dose can be drawn and administered. However, two separate vials should not be used to make up a full dose.

BOOSTER DOSES:

No booster doses are recommended at this time.

^A The vaccine series should be completed with the same COVID-19 vaccine product. If it is not possible to determine what product was used for the first dose, the second dose may be given with an available product.

^B An acceptable range for administration of the second dose is 28-42 days after the first dose. If administration of the second dose is delayed beyond 42 days, the second dose should be provided as soon as possible and the series does not need to be restarted.

^C The minimum interval between doses is 21 days. For optimal response, immunizers should observe recommended intervals as much as possible, however, doses given earlier than recommended may still be considered valid and need not be repeated if minimum intervals are observed.

COVID-19 (mRNA)

COVID-19 mRNA Vaccine mRNA-1273

Supplier: Moderna

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of the vaccine or to any component of the vaccine.

PRODUCT COMPONENTS:

Potential allergens: 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG).

Other components: cholesterol; 1,2-distearoyl-sn-glycerophosphocholine (DSPC); tromethamine; tromethamine hydrochloride; acetic acid, sodium acetate, sucrose.

PRECAUTIONS:

- For the following populations, a complete COVID-19 vaccine series may be offered to individuals in the authorized age group if a risk assessment deems that the benefits outweigh the potential risks for the individual, and if informed consent includes discussion about the absence of evidence on the use of COVID-19 vaccine in these populations:
 - immunosuppressed due to disease or treatment or those with an autoimmune disorder
 - pregnancy and breastfeeding (for more information see the [SOGC Statement on COVID-19 Vaccination in Pregnancy](#))
- Wait until symptoms of an acute illness are resolved before vaccinating with COVID-19 vaccine to differentiate symptoms of illness from vaccine side effects.
- There is insufficient evidence on the receipt of both a COVID-19 vaccine and any monoclonal antibodies or convalescent plasma for treatment or prevention of COVID-19. Therefore, timing of administration and potential interference between these two products are currently unknown and expert clinical opinion should be sought on a case-by-case basis.

SPECIAL CONSIDERATIONS:

- COVID-19 vaccines should not be given simultaneously with other live or inactivated vaccines. However, if a COVID-19 vaccine is inadvertently administered at the same time as another vaccine, neither dose should be repeated.
- Wait a period of at least 28 days after the administration of the complete two-dose vaccine series of an mRNA COVID-19 vaccine before the administration of another vaccine (except in the case where another vaccine is required for post-exposure prophylaxis) due to the elicitation of an inflammatory cytokine response. Wait for a period of at least 14 days after the administration of another vaccine before administering a COVID-19 vaccine.
- A complete series of COVID-19 vaccine may be offered to individuals without contraindications who have recovered from PCR-confirmed SARS-CoV-2 infection.
- Recipients should practice public health measures for prevention of SARS-CoV-2 infection and transmission regardless of vaccination with COVID-19 vaccine, at this time.

COVID-19 (mRNA)

COVID-19 mRNA Vaccine mRNA-1273

Supplier: Moderna

ADVERSE EVENTS:

Local: pain, swelling, redness.

Systemic: fatigue, headache, myalgia, chills, arthralgia, fever, nausea and vomiting.

REFERENCES:

1. [Moderna vaccine product monograph](#)
2. [National Advisory Committee on Immunization: Recommendations on the use of COVID-19 Vaccine\(s\)](#)